ClinicalTrials.gg
CompletedNCT05093634Updated Aug 6, 2026

EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

A Phase 3 interventional study of Setmelanotide and Placebo in Obesity and Genetic Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 56 sites in 10 countries. Open to participants aged 6 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
296
Allocation
Randomized
Ages
6 Years to 65 Years
Sex
All
01

Study summary

The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway:

  • POMC or PCSK1 (Sub-study 035a)
  • LEPR (Sub-study 035b)
  • SRC1 (Sub-study 035c)
  • SH2B1 (Sub-study 035d)

The objectives and endpoints are identical for these sub-studies.

02

Conditions studied

  • Obesity
  • Genetic Obesity

Browse trials for

Keywords

  • Melanocortin-4 Receptor Pathway
  • Genetic Obesity
  • Hunger
  • Hyperphagia
  • POMC
  • PCSK1
  • LEPR
  • SH2B1
  • NCOA1 (SRC1)
03

In context

Obesity

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's enrollment of 296 is above the median of 67 across 9,006 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 14 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients must have a pre-identified:

    • Heterozygous genetic variant in the POMC gene or PCSK1 gene
    • Heterozygous genetic variant in the LEPR gene
    • Homozygous, heterozygous, or compound heterozygous variant in the NCOA1 (SRC1)
    • Homozygous, heterozygous, or compound heterozygous variant in SH2B1 gene, or chromosomal 16p11.2 deletion encompassing the SH2B1 gene
  • Between 6 and 65 years of age at the time of provision of /assent
  • Obesity, defined as ≥30 kg/m2 for patients ≥18 years of age or BMI ≥95th percentile for age and gender for patients 6 up to 17 years of age
  • Patient and/or parent or guardian is able to understand and comply with the requirements of the study and is able to understand and sign the written informed consent/assent
  • Patient and/or parent or guardian reports that patient experienced childhood obesity, defined as the patient and/or parent or guardian reporting that the patient was significantly overweight during childhood
  • Agree to use a highly effective form of throughout the study and for 90 days following the study
  • Reported history of lifestyle intervention of diet and exercise
  • Reported history of hyperphagia

Key Exclusion Criteria:

  • Weight loss of 2% or greater in the previous 3 months
  • Recent history of bariatric surgery
  • Significant psychiatric disorder(s)
  • Suicidal ideation, attempt or behavior
  • pulmonary, cardiac, endocrine/metabolic, hepatic or oncologic disease
  • (HbA1C) >10% at Screening
  • History of significant liver disease or severe kidney disease
  • History or close family history (parents or siblings) of melanoma, or patient history of oculocutaneous albinism
  • Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)
  • Participation in any clinical study with an drug/device within 3 months prior to the first day of dosing
  • Previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide
  • Significant to any in the study drug
  • If female, pregnant or breastfeeding
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
296 participants (actual)

Study arms

  • Experimental
    POMC or PCSK1 variant

    1:1 Randomization

    Drug: Setmelanotide · Drug: Placebo

  • Experimental
    LEPR variant

    1:1 Randomization

    Drug: Setmelanotide · Drug: Placebo

  • Experimental
    NCOA1 (SRC1) variant

    1:1 Randomization

    Drug: Setmelanotide · Drug: Placebo

  • Experimental
    SH2B1 variant

    1:1 Randomization

    Drug: Setmelanotide · Drug: Placebo

Interventions

  • Subcutaneous Injection

  • DrugPlacebo

    Subcutaneous Injection

06

What researchers measure

Primary outcomes

  1. Difference in mean change in body weight in patients treated with setmelanotide compared to placebo, assessed as percent change in BMI

    Time frame: Baseline to 52 weeks

Secondary outcomes

  1. The proportion of patients who achieve at least 5% reduction in BMI in patients treated with setmelanotide compared to placebo

    Time frame: Baseline to 52 weeks

  2. The difference in mean change in body weight in adult patients treated with setmelanotide compared to placebo, assessed as percent change in baseline body weight

    Time frame: Baseline to 52 weeks

  3. The difference in mean percent change in the weekly average most hunger score in patients treated with setmelanotide compared to placebo

    Time frame: Baseline to 52 weeks

  4. The proportion of patients who achieve at least 10% reduction in BMI in patients treated with setmelanotide compared to placebo

    Time frame: Baseline to 52 weeks

07

Study locations

56 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • HonorHealth Bariatric Center
    Scottsdale, Arizona 85258, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Yale Center for Clinical Investigation
    New Haven, Connecticut 06519, United States
  • Advent Health
    Altamonte Springs, Florida 32701, United States
  • InQuest Medical Research
    Suwanee, Georgia 30024, United States
  • UMASS Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • University of Michigan
    Ann Arbor, Michigan 48105, United States
  • Metro Detroit Endocrinology Center
    Dearborn, Michigan 48126-2619, United States
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • St. Luke's Hospital
    Chesterfield, Missouri 63017, United States
  • Washington University in St. Louis
    St Louis, Missouri 63130, United States
  • University of Buffalo
    Buffalo, New York 14260, United States
  • Metropolitan Hospital Center
    New York, New York 10029, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Columbia University
    New York, New York 10032, United States
  • Ten's Medical Center - Pediatric Endocrinology Clinic
    Staten Island, New York 10306, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Geisinger Clinic
    Danville, Pennsylvania 17822, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Montefiore
    Pittsburgh, Pennsylvania 15213, United States
  • Vanderbilt University School of Medicine
    Nashville, Tennessee 37232, United States
  • Texas Tech
    Amarillo, Texas 79106, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Biopharma Informatic
    Houston, Texas 77084, United States
  • Rio Grande Valley Endocrine Center
    McAllen, Texas 78503, United States
  • Endocrine Associates of Dallas and Plano
    Plano, Texas 75093, United States
  • MultiCare Health System Institute for Research and Innovation
    Tacoma, Washington 98405, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
  • Marshfield Clinic Research Foundation, a Division of Marshfield Clinic, Inc
    Marshfield, Wisconsin 54449, United States
  • University of Alberta - Alberta Diabetes Institute (ADI)
    Edmonton, Alberta T6G 2E1, Canada
  • GH Est Hopital Femme Mere Enfant
    Lyon, 69677, France
  • Hu Pitie Salpetriere Aphp
    Paris, 75651, France
  • Hopital Armand Trousseau
    Paris, 75771, France
  • Centre Hospitalier Universitaire (CHU) de Bordeaux
    Pessac, 33604, France
  • Hôpital Félix Guyon Bellepierre
    Saint-Denis, 97400, France
  • Charite - Universitatsmedizin Berlin
    Berlin, 10117, Germany
  • Endokrinologikum Frankfurt
    Frankfurt, 60596, Germany
  • Universitaetsklinikum Leipzig
    Leipzig, 04103, Germany
  • Universitaetsklinikum Ulm
    Ulm, 89075, Germany
  • University of Patras School of Medicine
    Rio, 26504, Greece
  • Hasharon Hospital
    Petah Tikva, 49372, Israel
  • Chaim Sheba MC, Safra Children's Hospital
    Ramat Gan, 52621, Israel
  • Erasmus Medisch Centrum
    Rotterdam, 3015 GD, Netherlands
  • University of Puerto Rico
    San Juan, 00925-253, Puerto Rico
  • Hospital Sant Joan de Deu, Barcelona
    Barcelona, 08950, Spain
  • Hospital Fundación Jimenez Díaz
    Madrid, 28040, Spain
  • Hospital Universitario Virgen de la Victoria de Málaga
    Málaga, 29010, Spain
  • Hospital General de Valencia
    Valencia, 46014, Spain
  • Bristol Royal Hospital for Children
    Bristol, BS2 8AE, United Kingdom
  • University of Cambridge
    Cambridge, CB2 0QQ, United Kingdom
  • Aintree University Hospital
    Liverpool, L9 7AL, United Kingdom
  • London Medical - The London Diabetes Centre
    London, NW1 2PG, United Kingdom
  • University College London Hospitals NHS Foundation Trust
    London, WC1E6JF, United Kingdom
08

References and documents

Publications

  • Delplanque J, Le Collen L, Loiselle H, Leloire A, Toussaint B, Vaillant E, Charpentier G, Franc S, Balkau B, Marre M, Henriques E, Buse Falay E, Derhourhi M, Froguel P, Bonnefond A. Monoallelic pathogenic variants in LEPR do not cause obesity. Am J Hum Genet. 2024 Dec 5;111(12):2668-2674. doi: 10.1016/j.ajhg.2024.10.014. Epub 2024 Nov 18. PubMed 39561769 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Dec 2025, 48 months.

Of 198 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 48 months is above that.

Counting every sponsor, half of 261 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2021
First posted
Oct 26, 2021
StartActual
Dec 10, 2021
Primary completionActual
Dec 22, 2025
CompletionActual
Jun 30, 2026
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05093634
Responsible party
Sponsor
First posted
Oct 26, 2021
Start date
Dec 10, 2021
Primary completion
Dec 22, 2025
Completion
Jun 30, 2026
Last update
Aug 6, 2026

Study contacts

David Meeker, MD
study chair · Rhythm Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion